AI-CVD vs Ultrasound Workspace (UWS 6.0)
AI Verdict
Choose AI-CVD if…
Choose AI-CVD if your primary goal is to opportunistically screen for cardiovascular and multisystem diseases using existing CT scans, without requiring additional imaging, radiation, or workflow disruption. This tool is ideal for identifying hidden health risks and performing quantitative analyses like Coronary Artery Calcium (CAC) scoring and cardiac chamber volumetry from previously acquired chest and abdominal CT data.
View AI-CVD →Choose Ultrasound Workspace (UWS 6.0) if…
Choose Philips Ultrasound Workspace (UWS 6.0) if you need a comprehensive, AI-powered solution to streamline and standardize your echocardiography workflows across multiple vendors. This system is best suited for enhancing diagnostic confidence, improving reproducibility through automated measurements, and enabling flexible on-premise or web-based access for image review, analysis, and reporting in a dedicated echo lab setting.
View Ultrasound Workspace (UWS 6.0) →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AI-CVD | Ultrasound Workspace (UWS 6.0) |
|---|---|---|
| Deployment | Unknown | On-premise (single-seat workstation, multi-seat server) |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AI-CVDAI-CVD leverages existing CT scans for opportunistic screening, eliminating the need for additional imaging, radiation, contrast, or workflow disruption. This seamless integration into current clinical practices offers a significant advantage in usability compared to tools that require dedicated procedures or workflow adjustments.
Clinical Value
AI-CVDAI-CVD provides FDA-cleared opportunistic screening for cardiovascular and multisystem diseases using existing CT scans, enabling early detection of hidden health risks. This proactive identification of potential issues, such as Coronary Artery Calcium scoring and cardiac chamber volumetry, offers a broader and potentially earlier clinical impact than enhancing existing diagnostic echocardiography workflows.
Pricing & Value
Ultrasound Workspace (UWS 6.0)Both tools require contacting the vendor for pricing, limiting transparency. However, Philips Ultrasound Workspace explicitly states it is HIPAA compliant and has a Business Associate Agreement (BAA) in place, which provides clearer value and reduces procurement friction for healthcare organizations. AI-CVD only states these are 'likely' and require vendor contact for confirmation.
Enterprise Readiness
Ultrasound Workspace (UWS 6.0)Philips Ultrasound Workspace offers flexible deployment options (on-premise or server-client network with web-based access), explicit HIPAA compliance and BAA, and integration with existing PACS and EMR systems. This comprehensive approach, along with scalability and flexible licensing, demonstrates a higher level of enterprise readiness compared to AI-CVD's cloud-only deployment and less explicit integration details.
Innovation
AI-CVDAI-CVD's core innovation lies in its opportunistic screening capability, utilizing existing CT scans to detect hidden cardiovascular and multisystem diseases without additional procedures. This approach transforms underutilized data into actionable insights for early disease detection, representing a more novel application of AI in healthcare compared to enhancing existing echocardiography workflows.
Support & Docs
Ultrasound Workspace (UWS 6.0)Philips Ultrasound Workspace provides readily available documentation, including an Owner's Manual and DICOM conformance statements, and explicitly mentions technical support with contact information. In contrast, specific details regarding support and documentation for AI-CVD are not as explicitly detailed in the provided facts or public web searches.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AI-CVD | Ultrasound Workspace (UWS 6.0) |
|---|---|---|
| Name | AI-CVD | Ultrasound Workspace (UWS 6.0) |
| Company | HeartLung Corporation | Philips Ultrasound |
| Description | FDA-cleared, AI-powered quantitative imaging platform that performs opportunistic screening for cardiovascular and multisystem diseases using existing CT scans, enabling early detection of hidden health risks. | A holistic, scalable, AI-powered cardiovascular viewing, analysis, and reporting system designed to streamline echocardiography workflows, enhance diagnostic confidence, and improve reproducibility through vendor-neutral data analysis and flexible deployment. |
| Primary Imaging Modality | CT scans | Echocardiography (Ultrasound data) |
| Key Features (Cardiovascular) | Coronary Artery Calcium (CAC) scoring, Aortic wall, aortic valve, and mitral valve calcium analysis, Cardiac chamber volumetry (Left Atrium, Left Ventricle, Right Atrium, Right Ventricle), Epicardial fat volumetry, Aorta and pulmonary artery sizing. | AI-powered automated measurements (e.g., Auto Measure, AutoStrain LV, 3D Auto RV, 3D Auto MV, 3D Auto TV, 3D Auto CFQ), Comprehensive cardiovascular software solutions (review, image analysis, reporting, image management). |
| Opportunistic Screening | Yes, from existing chest and abdominal CT scans for cardiovascular and multisystem diseases. | Not specified |
| Vendor Neutrality | Not specified | Yes, vendor-neutral and multi-vendor data analysis for standardization. |
| Integration | No additional imaging, radiation, contrast, or workflow disruption. | Integration with existing PACS and EMR systems. |
Videos
Demos, reviews, and walkthroughs featuring AI-CVD and Ultrasound Workspace (UWS 6.0).